THE PARTICIPATION OF CHILDREN IN HIV/AIDS CLINICALS TRIALS: 
ETHICAL AND LEGAL CONSIDERATIONS

by

SANDRINE NTUMBA MUJINGA

Submitted in part fulfillment of the requirements for the degree of

MASTER OF LAW

In the subject

LEGAL ASPECTS OF HIV/AIDS

at the

UNIVERSITY OF SOUTH AFRICA

SUPERVISOR: PROFESSOR M.N. SLABBERT

JUNE 2009
DECLARATION AND COPYRIGHT

Student number: 4286-664-2

I, the undersigned, S. Ntumba Mujinga, hereby declare that THE PARTICIPATION OF CHILDREN IN HIV/AIDS CLINICALS TRIALS: ETHICAL AND LEGAL CONSIDERATIONS is my own original work and that it has not been presented at any other University for a similar or any other degree award, and that all the sources that have been used or quoted from have been acknowledged by means of complete references.

Signature (Mrs. S. Ntumba Mujinga) ........................

Date ...........................................................................
ACKNOWLEDGEMENTS

I am deeply grateful to many people who have gone out of their way to donate time, energy and effort to make this research a reality. I am especially indebted to The Lord Almighty who has made this study a success. I would like to express my profound thank to my supervisor Professor MN Slabbert, whose academic competence and guidance greatly contributed to the achievement of my LLM-degree and dissertation. I was particularly touched by her patience and encouragement.

It gives me great pleasure to thank Leanne Brown and Karen Beckon from the University of South Africa library for their library assistance.

Last, but not least, I thank my uncle, Makelele Kalala, and his wife, Ntumba Claudine, for assisting me to pursue my studies; my parents, Ntumba Mulume Pierre and Tekela Kalala Marie-Louise, for giving me life in the first place, for educating, support and encouragement to pursue my interests.

I will not forget my friends Aregbeshola Adewale, Kenedy Bindu, Jean-Remy Bosela, Emilie Kinfack, Carole Koumeb, Godefroid Yamulamba, Gerda Mpiana, Tanya Ondem and others who were always there for me.

DEDICATION

To Viana Balimaka Remy, with all my love, and to the children we will have together, I dedicate this dissertation.
SUMMARY

This dissertation examines the legal position relating to the participation of children in research, especially in HIV preventive clinical research in South Africa. HIV/AIDS presents a real threat to humanity and particularly to the welfare of children. The participation of children in this type of trials is therefore vital. Children, as vulnerable participants, must also be protected from harm resulting from research. The study also considers the nature of HIV preventive clinical research, pointing to the inconsistencies in the legislation governing children’s participation in HIV preventive vaccine trials. The dissertation concludes that the question of the participation of children in HIV preventive clinical research poses many challenges, as the position in the South African law and relevant ethical guidelines are inconsistent and contradictory. The study recommends in the final instance that the relevant statutory provisions and ethical guidelines be harmonised in order to clear up the inconsistencies.

KEY TERMS

HIV/AIDS; medical research; ethical guidelines; HIV preventive clinical trials; vaccine; informed consent; children.
# TABLE OF CONTENTS

DECLARATION AND COPYRIGHT ................................................................. 1  
ACKNOWLEDGEMENTS ............................................................................ 2  
DEDICATION............................................................................................... 2  
SUMMARY .................................................................................................. 3  
KEY TERMS ............................................................................................... 3  
TABLE OF CONTENTS .............................................................................. 4  

CHAPTER 1: INTRODUCTION .................................................................. 9  
  1 PROBLEM STATEMENT ........................................................................ 9  
  2 HYPOTHESES .................................................................................... 13  
  3 RESEARCH METHODOLOGY AND LIMITATIONS OF THE STUDY ...... 14  
  4 CONCEPTS DEFINED ......................................................................... 16  
    4.1 HIV AND AIDS ........................................................................... 16  
    4.2 CHILDREN .................................................................................. 17  
    4.3 INFORMED CONSENT ............................................................... 18  
    4.4 CLINICAL TRIALS .................................................................... 19  

CHAPTER 2: CLINICAL AND ETHICAL CONSIDERATION RELATING TO CLINICAL TRIALS ................................................................. 21  
  1 INTRODUCTION .............................................................................. 22  
  2 CLINICAL TRIALS ........................................................................... 22
2.5 NATIONAL HEALTH ACT ................................................................. 39
2.6 CHOICE ON TERMINATION OF PREGNANCY ACT .................. 40

3 CHILDREN’S PARTICIPATION IN RESEARCH .......................... 41
3.1 INTRODUCTION ................................................................. 41
3.2 CONSENT REQUIRED FOR MEDICAL RESEARCH .......... 42
3.3 DRAFT HEALTH RESEARCH REGULATIONS .................. 48
3.4 RISKS AND BENEFITS ....................................................... 49

4 RELEVANT CASE LAW .......................................................... 50
4.1 INTRODUCTION ................................................................. 50
4.2 CASTELL v DE GREEF ....................................................... 50
4.3 CV MINISTER OF CORRECTIONAL SERVICES .................... 51

5 CONCLUSION ................................................................. 52

CHAPTER 4: CONCLUSION AND RECOMMENDATIONS .................. 53
1 INTRODUCTION ................................................................. 53
2 SUMMARY ................................................................. 53
3 CONCLUSION ............................................................... 54
4 RECOMMENDATIONS ....................................................... 55

BIBLIOGRAPHY ........................................................................... 57
AIDS has changed Africa, and the world, forever. AIDS is not just another disease. It is the worst pandemic humanity has ever faced, and it is at the heart of the future development and identity of Africa. Across Africa there is a spirit of determination to at last attack the epidemic with full force. The planning phase is over. The time of small-scale pilot project is over. Full-scale engagement has begun.¹

CHAPTER 1
INTRODUCTION

Outline

1 Problem statement
2 Hypotheses
3 Research methodology and limitations of the study
4 Concepts defined
   4.1 HIV and AIDS
   4.2 Children
   4.3 Informed consent
   4.4 Clinical trials

1 PROBLEM STATEMENT

With more than 16 000 new people infected daily throughout the world, HIV/AIDS is clearly a disease of global significance, and is a major priority for the world community. Today, approximately 40 million adults and children are living with HIV/AIDS, and more than 28 million of those infected live in Sub-Saharan Africa. In terms of absolute numbers, South Africa has the highest population of people living with HIV/AIDS for a single country. In South Africa, children are the most vulnerable group, and are at great risk of HIV infection. HIV/AIDS is considered to be one of the greatest threats to the realisation of children’s rights in South Africa, because more than 40% of the population of approximately 45 million is under the age of eighteen, and they have an estimated HIV

---

infection rate of between 5 per cent and 15 per cent.\(^5\) This means that more than two million South African children under the age of eighteen could currently be infected with HIV.\(^6\) Thousands of babies are infected peri-natally. It is estimated that without antiretroviral treatment, about 30 per cent of babies born to infected mothers will themselves be infected. For example, of the total number of babies born in 2002, more than 90 000 of them were HIV positive.\(^7\) Although the Department of Health’s 2007 National HIV and Syphilis Antenatal Survey\(^8\) indicates a general decline in HIV prevalence from 2006-2007, the HIV prevalence estimate in older age groups (eg 30 – 34 and 35 – 39 years) is a concern as it remains at similar levels with a tendency towards an increase.\(^9\)

The combination of these factors shows one how alarming the situation is, and provides support for the claim that, for the common good of society, babies and young children should be the target population for HIV preventative vaccines. It is submitted that their enrolment in clinical trials would be a necessity in order to gather scientific data on the effect of HIV vaccines on preventing infections or diseases relevant to them. An effective preventative HIV vaccine could be a powerful tool in the struggle against the expanding HIV pandemic. The World Health Organization (WHO) takes the view that the participation of children is indispensable for research into diseases of childhood and conditions to which children are particularly susceptible.\(^10\) Research with children is also essential in order to determine the correct dose of medicines already used for adults. Simply adjusting for size is rarely adequate, as children differ from adults in terms of the


\(^6\) Van Wyk 35.


\(^9\) \textit{National HIV and Syphilis Survey} at 17-20.

rate at which they metabolise and eliminate some medicines.\textsuperscript{11} Young infants may eliminate medicines more slowly due to the immaturity of their liver and kidneys, while older infants and children eliminate some medicines more quickly. Therefore, in order to assess the safety and correct doses of medicines to be used in children, clinical trials have to be conducted, but only after trials have shown a good safety profile in adults.

However, although it has been established that vaccine trials may ultimately benefit children all over the world, especially in Africa where children are at a great risk of HIV/AIDS infection, their participation in this kind of research must be carried out in line with ethical standards. Vaccine development programmes should explore the legal, ethical and health considerations relevant to their participation in vaccine research. Because of their vulnerable situation, the potential exists that participants in HIV vaccine efficacy trials in South Africa may be exploited.\textsuperscript{12} The risks and benefits of children’s participation in such trials must be carefully considered.

Section 12(2)(c) of the Constitution\textsuperscript{13} provides that everyone has the right to physical and psychological integrity, which includes the right not to be subjected to medical or scientific experiments without their informed consent. The informed consent of people participating in research is essential. Where such consent cannot be obtained due to the incapacity of the participant (in the case of children), proxy consent of a parent or guardian is recommended.\textsuperscript{14} Informed consent is regarded as one of the primary ways of ensuring that research participants are protected against exploitation.\textsuperscript{15}

The position regarding the informed consent of children who are participating in research seems to be unclear. This situation is due to the contradictory and inconsistent nature of

\begin{itemize}
\item \textsuperscript{11}Smith 175. See also Kauffman R E “Drug trials in children: ethical, legal, and practical issues” (1994) 34(4) 296-299.
\item \textsuperscript{12}Nienaber A G \textit{Ethics and human rights in HIV-related clinical trials in Africa with specific reference to informed consent in preventative HIV vaccine efficacy trials in South Africa} (LLD-thesis Pretoria: University of Pretoria 2007) 360.
\item \textsuperscript{13}of the Republic of South Africa, 1996.
\item \textsuperscript{14}See Van Wyk “HIV preventative vaccine research on children: Is it possible in terms of South African law and research guidelines?” at 49.
\item \textsuperscript{15}See Nienaber at 360.
\end{itemize}
South African law and relevant ethical guidelines. Guidelines 18.7.2.1 and 18.7.3\textsuperscript{16} of the Medical Research Council’s Guidelines on Ethics for Medical Research (HIV Preventive Vaccine Research)\textsuperscript{17} contrast sharply with the conditions laid down by the National Health Act\textsuperscript{18} in section 71\textsuperscript{19} and by the Children’s Act\textsuperscript{20} in sections 129(2) to 129 (3).\textsuperscript{21} For example, the National Health Act makes no distinction between children above and below the age of 14, and requires, in the case of non-therapeutic research on children, the consent of the Minister of Health. On the other hand, guideline 18.7.3 of the Medical Research Council’s Guidelines\textsuperscript{22} requires, for non-therapeutic research, the proxy consent of parents and the agreement of the child for participation.

With regard to the nature of HIV vaccine research and the level of risks relating to this type of research, the research question is as follows:

Is the enrolment of healthy children in HIV vaccine trials permitted in the light of the South African Constitution, current legislation and relevant guidelines?

The nature of these trials must be also considered. There is presently no agreement on
whether HIV preventative vaccine trials should be classified as therapeutic or non-therapeutic research. According to guideline 9.8 of the MRC’s Guidelines (see Book 5 of the revised guidelines) HIV preventive vaccine is considered as research of a non-therapeutic nature. This point of view is also shared by Van Wyk, who states that “part from the unacceptable level of risks, preventive vaccine research is by its very nature interventional research, which in terms of the MRC guidelines, should never be allowed on children.”

Those who view these trials as therapeutic argue that participants in such trials need to be at high risk of HIV infection, in order to ensure the degree of effectiveness of the vaccine. They are at increased risk of infection because of their lifestyle or because of social, cultural and economic circumstances. For this reason, they will benefit from the purpose of the research, namely an effective, preventative HIV vaccine and such research should therefore be considered to be “therapeutic”.

2 HYPOTHESES

2.1 A less restrictive interpretation of section 12(2)(c) of the Constitution would allow children to give their own informed consent to all medical research. Informed consent is a well-established requirement for the ethical conduct of research. At an international and local level, ethical guidelines on informed consent provide guidelines for the protection of participants in HIV vaccine trials in South Africa.

2.2 Given the threat of the HIV/AIDS epidemic to children, it is deemed critical by scientists that children and neonates are enrolled in clinical trials in order to generate safety, immunogenicity and efficacy data relevant to them. Because of

---

27 Van Wyk 38
28 Nienaber 393.
29 Van Wyk 36.
the stigma attached to HIV infection and the victimisation of people who are (or are perceived to be) HIV positive, the rights of participants in the various trials must be held sacrosanct, as must those of the community in which HIV vaccine trials are conducted.\textsuperscript{30} Risk should be balanced with the potential benefit that may accrue from HIV vaccine trial participation.\textsuperscript{31} Preventative HIV vaccine trial participation has the potential to benefit the individual participant and the community in a number of ways,\textsuperscript{32} notably:

\begin{enumerate}
\item Increased feeling of self-worth because the trial participant is helping others;
\item Increased access to and better quality health care;
\item Counseling on risk-taking behaviours;\textsuperscript{33}
\item Increased community awareness of scientific and epidemiological aspects of HIV;
\item An efficacious HIV preventative vaccine. This benefit suggests why preventative HIV vaccine trials are going ahead and attracting participants, despite the precarious nature of the knowledge so far gained about the possible risks and side-effects of these trials.\textsuperscript{34}
\item Guaranteed access to antiretroviral treatment if and when required; and
\item The knowledge that the child is contributing to the advancement of science and the attempt to halt the progression of widespread disease.\textsuperscript{35}
\end{enumerate}

\section{RESEARCH METHODOLOGY AND LIMITATIONS OF THE STUDY}

This study - a dissertation of limited scope - involves a literature review of relevant text

\begin{thebibliography}{99}
\item Nienaber at 5.
\item Nienaber at 338.
\item Nienaber 338.
\item In this regard, see also Francis D P \textit{et al} “Candidate HIV/AIDS vaccines: Lessons learned from the World’s first phase III efficacy trials” (editorial review) (2003) 17 \textit{The Lancet} 153.
\item Nienaber 340.
\end{thebibliography}
books, journal articles and case law. The study provides a critical analysis of the relevant South African literature and case law relating to children’s participation in HIV preventative vaccine trials. A review of the literature has revealed that not much has up to date been written on the legal aspects relating to children’s participation in HIV vaccine trials.\(^{36}\) Although it has been established that the number of South African children being infected by HIV is high, as is extremely important for these children to participate in preventative HIV vaccine clinical trials, most international HIV vaccine trials conducted so far have focused on adults, a few on neonates, and none on adolescents.\(^ {37}\) As it has not yet been proven that the immune response of adolescents and adults is similar, adult data on vaccine trials cannot necessarily be extrapolated to adolescents.\(^ {38}\) The ethical-legal complexities regarding the participation of children in HIV vaccine trials merit the evaluation of the level of research-related risk, and the informed consent of the participant.

A number of articles published recently and to which this study will refer deal with adolescent preventative HIV vaccine trials in South Africa, highlighting the increasing incidence of HIV infection in this particular age group. Others investigate the implications of the new National Health Act, the Constitution and local and international ethical guidelines regarding children’s vaccine trial participation and the notions of risk and informed consent. Similarly, this mini-dissertation will focus on the legal and ethical questions of South African children’s participation in preventative HIV vaccine trials.

The narrow scope of this study does not, unfortunately, permit an analysis of all the relevant fundamental rights of children that are implicated in this study, such as the right to freedom and security of the person (section 12), the right to privacy (section 14), human dignity (section 10), right to access to health care services (section 27(1)(a)), as well as relevant rights relating to children specifically under section 28 of the South African Constitution. The discussion will be limited to those issues related to section 12

\(^{36}\) Legal publications dealing with this topic specifically are limited to those contributions by Nienaber and Van Wyk (referred to extensively in this study).

\(^{37}\) Van Wyk 36.

\(^{38}\) Van Wyk 36.
of the Constitution, as discussed in chapter three below.

Chapter two of this study will examine relevant clinical and ethical considerations relating to HIV vaccine efficacy clinical trials, as well as determine whether this kind of research falls into the category of therapeutic or non-therapeutic research. Relevant international and domestic guidelines relating to research involving human subjects will also be explored in this chapter.

Chapter three will examine specific legislative provisions relating to children’s participation in research, the issue of informed consent, and relevant case law.

Chapter four will present a summary and recommendations following from the problems and lacunae identified in the first three chapters.

4 CONCEPTS DEFINED

It is necessary at the outset of the study to explain the central concepts of this study in more detail. These concepts are HIV and AIDS, the reference to “children” in this study, the concept of informed consent, and finally, the term “clinical trials”.

4.1 HIV AND AIDS

AIDS is the acronym for the Acquired Immune Deficiency Syndrome. This disease is called acquired because it is not a disease that is inherited. It is caused by a retrovirus, HIV (Human Immunodeficiency Virus) that enters the body from outside. Immunity is the body’s natural ability to defend itself against infection and disease. A deficiency is a shortcoming - the weakening of the immune system, so that it can no longer defend itself against opportunistic infections.39 A syndrome is a medical term for a collection of specific signs and symptoms that occur together and that are characteristic of a particular

condition. Although the term “disease” is used when one talks about Aids, it is in reality not a specific illness. It is a collection of many different conditions that manifest themselves in the body (or specific parts of the body), because HIV has so weakened the body’s immune system that it can no longer fight the disease-causing agents that are constantly attacking it.

HIV can be found in the following body fluids with a sufficient concentration to be able to be transmitted: blood, semen, vaginal and cervical discharges and breast milk. It is transmitted in the following ways:

- Unprotected sexual intercourse;
- Receipt of or exposure to the blood, blood products semen, tissues or organs of a person with HIV, syringes and/or needles for intravenous drugs, or by injecting infected blood;
- From a mother to her fetus before birth, or to her baby during birth, or after birth by breastfeeding.

### 4.2 CHILDREN

The Children’s Act states in section 17 that legal majority is attained at the age of eighteen. Thus, a child or minor is henceforth a person below eighteen years of age. References in this study to a child or children hence refer to a person below the age of eighteen years.

---

40 Van Dyk 3.
41 Van Dyk at 4.
43 38 of 2005.
4.3 INFORMED CONSENT

Consent is a ground for justification which excludes the unlawfulness of an action that would otherwise amount to a delict. The person suffering harm waives his or her right, to the extent that he or she permits another person to violate his or her interests. The person thus committing the act cannot be held liable for any damage caused. The principle that such a person is not culpable when the injured person has consented to the injury or risk to injury, is embodied in the maxim volenti non fit iniuria (i.e. a willing person is not wronged), which forms part of South African law.

Informed consent in the context of vaccine trials means that the research participants should know that they are taking part in a research project. The nature and purpose of and all relevant information about the research must be provided to them. Thus, they will be able to assess the risks and benefits of participating in this kind of research. Time for reflection should also be given to them, and they should be told that they can withdraw at any time without penalty. Sections 129(2) and 129(3) of the Children’s Act specifically require the capacity of the child (of twelve years and older) to understand the relevant benefits and risks involved in a medical intervention or research. However, even if mature, some children may not be able to understand the importance to participate in certain types of research or trials, or the relevant risks which can result from these.
Section 12(2)(c) of the Constitution\textsuperscript{48} provides that everyone has the right to physical and psychological integrity, which includes the right not to be subjected to medical or scientific experiments without their informed consent. The informed consent of people participating in research is essential. Where such consent cannot be obtained due to the incapacity of the participant (in the case of children), the proxy consent of a parent or guardian is recommended.\textsuperscript{49} Informed consent is regarded as one of the primary ways of ensuring that research participants are protected against exploitation.\textsuperscript{50}

The position regarding the informed consent of children who are participating in research appears to be unclear. This issue will be discussed in detail in chapter three below.

4.4 CLINICAL TRIALS

The terms “clinical research” and “clinical trials” are referred to in this study.

4.4.1 Clinical research

This term refers to research “involving human subjects that is designed either to enhance the professional capabilities of individual physicians or to contribute to the fund of knowledge in those sciences that are traditionally considered basic”.\textsuperscript{51} Clinical research is thus research carried out on humans, and, by definition, therefore excludes research carried out on human blood or tissue samples and research on animals.\textsuperscript{52} It is also carried out on healthy individuals in order to expand scientific knowledge. The benefit of clinical research is for the individuals who are taking part in the research, or society as a whole.

\textsuperscript{48} Of the Republic of South Africa, 1996.
\textsuperscript{49} Van Wyk 49.
\textsuperscript{50} Nienaber 360.
\textsuperscript{51} Levine R J \textit{Ethics and the regulation of clinical research} (2\textsuperscript{nd} ed) (1981, Baltimore: Urban & Schwarzenberg), cited by Nienaber at 64.
\textsuperscript{52} Levine, cited in Nienaber 64..
Clinical trials can be defined as trials conducted to test drug safety and efficacy in humans. They provide the first opportunity to introduce an experimental substance to human beings. The internationally accepted standard for vaccine research involving human subjects typically requires that human trials be done in three phases:

- Phase I studies usually involve only a few human subjects, all of whom are healthy. In HIV vaccine studies, subjects in phase I trials will probably also show no known risk factors or behaviour.
- Phase II trials continue to study safety, but the additional foci of this phase are also dosage and immunogenicity, e.g. proper dosage levels and effectiveness in stimulating some kind of immune response. If a vaccine candidate shows promise in phase II trials as well, it may then go on to be tested in phase III.
- Phase III trials, sometimes called efficacy trials, are intended for a more complete assessment of safety and effectiveness in the prevention of disease, involving a larger number of volunteers in a multicentre adequately controlled study.

The next chapter will briefly explore the nature of HIV preventive vaccine trials with the purpose of answering the question whether such trials are considered to be therapeutic or non-therapeutic in terms of national and international guidelines.

---

54 Kerns TA Ethical issues in HIV vaccines trials (1997, Seattle: North Seattle Community College) at 72.
## Outline

1. **Introduction**

2. **Clinical research**
   - 2.1 Introduction
   - 2.2 Types of clinical research
     - 2.2.1 Clinical drug trials
     - 2.2.2 Clinical vaccine trials
   - 2.3 Preventive HIV vaccine efficacy trials
   - 2.4 Phases in clinical trials
     - 2.4.1 Phase I
     - 2.4.2 Phase II
     - 2.4.3 Phase III

3. **Therapeutic and non-therapeutic research**
   - 3.1 Introduction
   - 3.2 Classification
     - 3.2.1 Medical Research Council: Guidelines
     - 3.2.2 Scholarly views
   - 3.3 Children and HIV preventive vaccine trials

4. **Ethical Guidelines and Documents**
   - 4.1 Introduction
   - 4.2 International codes of ethics
     - 4.2.1 Nuremberg code
     - 4.2.2 Declaration of Helsinki
     - 4.2.3 Belmont Report
     - 4.2.4 International Ethical Guidelines for Biomedical Research Involving Human Participants
   - 4.3 Domestic codes of ethics
     - 4.3.1 MRC Guidelines
     - 4.3.2 Good practice guidelines

5. **Conclusion**
1 INTRODUCTION

Medical experimentation, which has been recorded as far back as the time of Hippocrates, demands the striking of a delicate balance between the need to advance medical science and the equally important need to protect the inherent dignity and integrity of the individual.\(^{55}\) Clinical research refers to research involving human subjects, and which is designed either to enhance the professional capabilities of individual physicians or to contribute to the fund of knowledge in those sciences that are traditionally considered to be basic.\(^{56}\) From this definition it is clear that the individual research participant might not benefit directly from the research that is being conducted - research may be undertaken in order to contribute to the “fund of knowledge.”\(^{57}\) It is also important to note that clinical research is sometimes carried out with healthy individuals who are exposed to risk solely to expand scientific knowledge.\(^{58}\)

This chapter will address the relevant ethical considerations relating to HIV vaccine efficacy clinical trials and determine whether this kind of research falls into the category of therapeutic or non-therapeutic research. Because of their particular nature, HIV vaccine efficacy trials offer some benefits and pose specific risks for participants. Relevant international and domestic guidelines relating to research involving human subjects will also be explored in this chapter.

2 CLINICAL TRIALS

2.1 INTRODUCTION


\(^{56}\) Nienaber AG Ethics and human rights in HIV-related clinical trials in Africa with specific reference to informed consent in preventative HIV vaccine efficacy trials in South Africa (LLD-thesis Pretoria: University of Pretoria 2007) 64. See also in general, Rick N G Drugs from discovery to approval (2004, New Jersey:John Wiley & Sons).

\(^{57}\) Nienaber 64.

\(^{58}\) Nienaber 65.
As argued in the previous chapter, the only hope of arresting the alarming spread of HIV is the development of an effective vaccine. Vaccine development involves steps such as basic research, pre-clinical evaluation and production, and clinical trials with human subjects. It is recognised that without research involving human subjects, major medical breakthroughs would never have been achieved. Historically, clinical research has led to the development of drugs, such as antibiotics and antiviral drugs, as well as procedures such as heart and lung transplants. Thus, neglecting this kind of research will have disastrous effects.

2.2 TYPES OF CLINICAL TRIALS

Two kinds of clinical trials can be identified, namely clinical drug trials and clinical vaccine trials. The difference between these two types of clinical trials bears on the composition and size of sample and to whom it will benefit.\(^{59}\) In the context of this study, the focus will be on the vaccine efficacy trials which fall within the ambit of the present topic.

2.2.1 Clinical drug trials

Clinical drug trials are designed to test drug safety and efficacy in human subjects. Subjects recruited for participation in clinical drug trials, at least at the stage of establishing and confirming efficacy, almost always have the disease the drug is designed to treat.\(^{60}\) Despite the concerns of some that illness makes them vulnerable to undue influences, subjects are nevertheless patients in need of treatment, and although the effectiveness of the drug is uncertain, it is perhaps one of the very few options which could benefit them directly.\(^{61}\) Finding an effective therapy has potential immediate benefit for an individual with the given disease, and potential future benefits for the


\(^{60}\) Grady 65.

\(^{61}\) Grady 65.
group of individuals who have the disease, and for society at large, because of the advancement of useful knowledge.\textsuperscript{62}

2.2.2 Clinical vaccine trials

Clinical vaccine trials are designed to test vaccine safety and effectiveness in human subjects. Subjects recruited for participation in this kind of trial are healthy volunteers who are at risk of the disease which the vaccine is designed to prevent.\textsuperscript{63} It is also possible that they will never be exposed to, or infected with, the putative agent, or that it could only occur many years later.\textsuperscript{64} Subjects in vaccine research accept some risk and uncertainty for the possibility of a potential future benefit which they may never need. The community or the society is the primary beneficiary from this research by reducing risk and disease, and for the advancement of usable knowledge.

2.3 PREVENTIVE HIV VACCINE EFFICACY TRIALS

The benefits of funding an effective preventive vaccine for HIV are enormous, both for the individual and for society. The successfully vaccinated individual will be protected against future infection and non-vaccinated members of society will be protected, as the ‘pool’ of infection will have been decreased.\textsuperscript{65}

To assess the efficacy and safety of the vaccine, it must be important to conform to the procedure established. The internationally accepted standard for vaccine research involving human subjects requires that human clinical trials have to follow three phases. These phases are important to be respected because of the registration and the license for general public use of the vaccine.

\textsuperscript{62} Ibid.
\textsuperscript{63} Grady 65.
\textsuperscript{64} Ibid.
2.4 PHASES IN CLINICALS TRIALS

2.4.1 Phase I: Clinical pharmacology

This phase assesses the safety (or toxicity) of the vaccine, and the immune system’s response to it. At this stage, the trial has to determine that the test vaccine does not produce side effects in human participants. This phase lasts about eighteen months to two years, and the number of trial participants is smaller, compared with the other phases. In addition, as efficacy is not at issue here, trial participants do not need to be at a high risk of HIV infection.

2.4.2 Phase II: Clinical investigation

This phase is generally intended to study potency and immunogenicity, and to determine appropriate doses and routes of administration, with the possibility of collecting data on potential effectiveness. Trials are conducted with larger numbers of closely monitored participants, some of whom should be at high risk of HIV infection. The duration of this phase is about twenty-four months.

2.4.3 Phase III: Clinical trial

This trial assesses efficacy (whether the vaccine will prevent HIV infection or slow down or prevent disease progression). A large number of trial volunteers are used during

---

67 Van Dyk 21.
68 Mostly less than a hundred, usually twenty to fifty participants.
69 Nienaber 73.
70 Such as immune system’s responses against HIV.
72 Usually hundreds of participants.
73 Nienaber 73.
75 Van Dyk 21.
this stage, and these volunteers should be at a high risk of HIV infection. The duration of
this phase is usually three to four years or more.\textsuperscript{77}

Because of their particular nature, HIV vaccine efficacy trials offer some benefits and
pose specific risks for participants. Some of these are mentioned below, paving the way
for the subsequent a detailed examination of the benefits and risks of participation (see
chapter 3 below).

3 THERAPEUTIC AND NON-THERAPEUTIC RESEARCH

3.1 INTRODUCTION

Two types of research involving human subjects can be identified. The one is carried out
for the benefit of the patient/subject, and is called therapeutic research. Therapeutic
research is undertaken in a controlled manner, often as a randomized, clinical trial.\textsuperscript{78}
Non-therapeutic research, on the other hand, is performed in order to acquire knowledge
which, during the course of the experiment at least, is of no benefit to the subject.\textsuperscript{79}

3.2 CLASSIFICATION

The classification of clinical research into “therapeutic” or “non-therapeutic” has
important implications, not only for consent issues, but also for the evaluation of risk and
benefit, as different kinds of research involve different levels of risk.\textsuperscript{80} It is therefore
relevant to ascertain in which category of research HIV vaccine efficacy trials belong.
The discussion that follows will turn to the relevant ethical guidelines and scholarly
opinion on the classification of HIV preventive vaccine trials as “therapeutic” or “non-
therapeutic” research. Although it is often difficult to distinguish between these two

\textsuperscript{76} Trial volunteers may include up to thousands of participants.
\textsuperscript{77} Van Dyk at 22.
\textsuperscript{78} Oosthuizen G C, Shapiro H A \& Strauss S A (eds) \textit{Attitudes to clinical experimentation in
South Africa} (1985, Cape Town: Hodder and Stougthon ) at 35.
\textsuperscript{79} Oosthuizen 35.
\textsuperscript{80} Nienaber 486.
categories of research, it can be argued that therapeutic research involves direct benefit to
the individual research participant and the latter cannot be exposed to a greater than
minimal risk. In the case of non-therapeutic research that aims to benefit other people
than the research participant and which aims to generate knowledge, the participant may
be subjected to no more than minimal risk.

3.2.1 Medical Research Council: Guidelines

The MRC was created by the section 2 of the South African Medical Research Council
Act, with the objective to improve the nation’s health and quality of life trough
promoting and conducting relevant and responsive health research. The Ethical
Guidelines of the Medical Research Council states that the benefits likely to accrue to the
participant should outweigh the risk of harm. Normally, research involving patients
should not involve risk that is greater than minimal. In non-therapeutic research the
healthy volunteer may be subjected to no more than minimal risk as a result of
participation.

Although the difference between therapeutic and non-therapeutic research in the context
of risk analysis and an individual’s decision as to whether or not to participate in the
research is generally acknowledged, the difference in practice is, however, seldom clear-
cut. This distinction between therapeutic and non-therapeutic research is often made in
South African ethical discourse, as well as in legislation. The question arising is into
which category preventive HIV vaccine efficacy trials would fall - are such trials to be

---

81 Guideline 9.12.4.4 of the MRC’s Guidelines on Ethics for Medical Research: General
principles (Book 1).
82 Ibid.
83 Act 19 of 1969, which is the predecessor of the present Act (Act 58 of 1991).
84 For an overview of the Medical Research Council and its operations, see in general
85 MRC Guidelines on Ethics for Medical Research: General principles (Book 1), guideline
9.12.4.4.1.
86 Guideline 9.12.4.4.2 of Book I.
87 Guideline 9.12.4.5.1.
88 See, for example, sections 71(2) and 71(3) of Act 61 of 2003, which also distinguishes
between therapeutic and non-therapeutic research.
regarded as therapeutic or non-therapeutic? This issue, considered next, has led to much uncertainty among South African scholars.

3.2.2 Scholarly views

One prominent South African legal scholar\(^\text{89}\) states that because of the unacceptable level of risks, preventive vaccine research is by its very nature interventional research, and should never been allowed on children. Some scholars have cogently argued that instead of attempting to classify whole protocols as “therapeutic” or “non-therapeutic”, one should ascertain whether or not particular research interventions intend to confer direct health-related benefits.\(^\text{90}\) According to Levine, this classification has several unfortunate (and unintended) consequences.\(^\text{91}\)

For the purpose of this study the question is whether it is possible to argue that HIV vaccine efficacy trials are “therapeutic” research and hence justify a greater risk of harm to the individual. As seen above, preventive HIV vaccine efficacy trial participants need to be at risk of HIV infection in order to ensure that the effectiveness or not of the vaccine may be statistically proven. They should be at great risk of HIV infection because of their lifestyle or because of their social, cultural and economic circumstances.\(^\text{92}\) Some scholars argue that for this reason they benefit from the object of research funding an effective HIV vaccine, and that such research should therefore be considered to be “therapeutic”.\(^\text{93}\) Even if participants at high risk of HIV infection do not personally benefit, the class of subjects to which they belong – be it injection drug users (IDU), men who have sex with men (MSM), or the particular community in which they live - may potentially benefit from the research, as they will be given counseling on high

\(^{89}\) Van Wyk 49.


\(^{93}\) Ibid.
risk behaviors (a “therapeutic” intervention), and thus (it is hoped) reducing their chance of infection.\textsuperscript{94} On the whole, it will be difficult to fit HIV-preventive clinical trials into the category of either “therapeutic” or “non-therapeutic” research.\textsuperscript{95}

Moreover, some types of preventive HIV-related research (such as research to find a microbicide against HIV-infection) may arguably be considered “therapeutic” research, whereas other types of HIV-related clinical research (such as preventive HIV-vaccine research) may be considered “non-therapeutic”\textsuperscript{96}.

\section*{3.3 CHILDREN AND HIV PREVENTIVE VACCINE TRIALS}

Stobie, Strode and Slack\textsuperscript{97} point out that in a context of frequently inadequate primary health care, the benefits of participating in HIV vaccine trials should not be underestimated, and that these are arguably in the “best interests” of the child trial participant. In addition, they assert that whole protocols should not be evaluated as being “therapeutic” or non-therapeutic. The most important thing to assess is whether the participation of children in a specific kind of research is in their best interests or not.

The next section will examine the relevant international and domestic guidelines on research involving human beings.

\section*{4 ETHICAL GUIDELINES AND DOCUMENTS}

\subsection*{4.1 INTRODUCTION}

Research involving human beings as subjects has produced substantial social benefits, and has made an enormous contribution to human development. However, research involving human subjects can lead to possible abuse of the participants. There is hence a

\begin{footnotesize}
\textsuperscript{94} Nienaber 489.
\textsuperscript{95} Nienaber A “The statutory regulation of children’s participation in HIV-related clinical research: More questions than answers” 2008 (71) \textit{THRHR} 671-674 at 675.
\textsuperscript{96} Nienaber “The statutory regulation of children’s participation” 675.
\textsuperscript{97} Stobie, Strode & Slack at 197.
\end{footnotesize}
need for ethical principles to guide scientific investigations in order to prevent any kind of abuse. In South Africa, clinical trials with human subjects to establish the efficacy or safety (or both) of new drugs (such as vaccines) is governed by legislation\(^\text{98}\) as well as by international and national principles and guidelines for medical and research ethics.

International documents, such as the Nuremberg Code; the Council for International Organizations of Medical Sciences (CIOMS); the International Ethical Guidelines for Biomedical Research involving Human Subjects; the Belmont Report and the Declaration of Helsinki, are next scrutinized, as well as domestic documents such as the Medical Research Council’s Guidelines on Ethics for Medical Research (2002).

### 4.2 INTERNATIONAL CODES OF ETHICS

#### 4.2.1 Nuremberg Code

The Nuremberg Code, written in 1946 as the final part of the judgment in the Nuremberg Trials,\(^\text{99}\) proposed minimal ethical conditions for medical studies on human subjects, and these are now reflected in the policies of all countries and the laws of many of these jurisdictions.\(^\text{100}\)

This code is a consequence of the cruel and inhuman nature of the experiments conducted during the Second World War in Nazi Germany. The Nuremberg Code contains ten principles. Article two of the Code provides that human experimentation should be conducted ethically, and cannot be obtained by any other means, and it forbids research that is random and unnecessary. The degree of risk should never exceed that determined by the humanitarian importance of the problem to be solved by the experiment.

---

\(^{98}\) Eg, the Medicines and Related Substances Control Act 101 of 1965, National Health Act 61 of 2003 and Promotion of Access to Information Act 2 of 2000.

\(^{99}\) The Nuremberg Trials included the trials of doctors responsible for some of the inhuman experiments conducted at the orders of the Nationalist Socialist German Government during World War II.

4.2.2 Declaration of Helsinki

The Declaration of Helsinki, which was adopted in 1964 by the World Medical Association’s 18th Assembly as a further measure to the Nuremberg Code to protect society against abuse, consists of three sections. Section 1 covers basic principles; section 2 deals with medical research combined with clinical care (clinical research); and section 3 examines non-therapeutic biomedical research involving human subjects (non-clinical biomedical research). Unlike the Nuremberg Code, the Declaration of Helsinki distinguishes clinical (therapeutic) from non-clinical (non-therapeutic) research.

According to the section 3(1), medical research carried out on a human being must ensure that the individual participating must be protected against any kind of harm. Sections 3(3) and 3(4) state that the research should be discontinued by the investigator or the investigating team if in his/her or their judgment it may, if continued, be harmful to individual. The interests of science and society should never take precedence over the well-being of the research subject.

4.2.3 Belmont Report

In 1979, the American National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research published the Belmont Report on Ethical Principles and Guidelines for the Protection of Human Subjects of Research (Belmont Report). Three fundamental ethical principles were described as being particularly relevant to the ethics of research involving human subjects: respect for persons; beneficence; and justice.

---

101 The Declaration has been revised several times, most recently in October 2000 and “Clarifications” have also been added to the 2000 revision, accepted in October 2002. See in this regard, Nienaber at 99.


103 Nienaber Ethics and human rights in HIV-related clinical trials in Africa with specific reference to informed consent in preventative HIV vaccine efficacy trials in South Africa at 101.
4.2.4  International Ethical Guidelines for Biomedical Research involving Human Participants

The Council of International Organizations of Medical Sciences (CIOMS), in conjunction with the World Medical Association (WMA), published its International Ethical Guidelines for Biomedical Research involving Human Subjects (CIOMS Guidelines) in 1982, and updated these guidelines in 1993 and 2002.\textsuperscript{104} This document contained 21 guidelines, and issues discussed are, among others, validity of research,\textsuperscript{105} benefits and risk of participation\textsuperscript{106} and children and women as research participants.\textsuperscript{107} According to guideline 5, which deals specially with the participation of children in research, the participation of children is indispensable for research into childhood and conditions to which children are particularly susceptible. The aims of the research should be relevant to the health of the children. The participation of children is conditioned by the obtaining of own informed consent of the children or proxy consent of the parents, guardian or caregiver. In the case of therapeutic research, risks are to be justified in relation to anticipated benefits to the child. In case of research not intended to benefit directly the child-subject, the risk following from such interventions should be minimal.

4.3  DOMESTIC CODES OF ETHICS

4.3.1  MRC GUIDELINES

The MRC Guidelines on Ethics for Medical Research which is issued by the Medical Research Council Act\textsuperscript{108} has under its control all research carried out by or on the behalf of the MRC.\textsuperscript{109} These guidelines are considered as one of the most important in the sphere of research in South Africa. The fourth edition of the MRC guidelines was recently published. The revised MRC Guidelines contain five books. Book five, entitled

\textsuperscript{104} Nienaber 101.
\textsuperscript{105} Guideline 1, CIOMS Guidelines.
\textsuperscript{106} Guidelines 8-9, CIOMS Guidelines.
\textsuperscript{107} Guidelines 14-16, CIOMS Guidelines.
\textsuperscript{108} Medical Research Act 58 of 1991.
\textsuperscript{109} Van Oosten F “The law and ethics of information and consent in medical research” (2000) 63 THRHR 5-31, at 7-8.
Guidelines on Ethics for Medical Research: HIV Vaccine Trials, is important in the context of this study, as it deals with the participation of children in HIV vaccine efficacy trials, which will be examined in detail in the next chapter.

4.3.2 Good Practice Guidelines

The Guidelines for Good Practice in the Conduct of Clinical Trials on Human Participants in South Africa (Good Practice Guidelines) was issued by the Department of Health (DOH).\footnote{Issued in September 2000.} This document attempts to address several ethical issues relating to HIV/AIDS clinical and epidemiological research in South Africa.\footnote{Guideline 9.1 of the \textit{Good Practice Guidelines} states: “This document attempts to address several ethical issues relating to HIV/AIDS clinical and epidemiological research in South Africa. There are also national and international vaccine initiatives in South Africa. This will stimulate the development of appropriate ethical considerations relating to vaccine research. With many ethical issues there are not always clear right or wrong answers. There are however several universally accepted ethical principles. These principles should be applied within the context of South Africa and this document is intended to facilitate a more uniform approach to common ethical issues relating to HIV/AIDS related research.”} Its preamble states that the guidelines are aimed at providing South Africa with “clearly articulated standards of good clinical practice in research that are also relevant to local realities and context.”\footnote{See Preamble to the \textit{Good Practice Guidelines}.} Although the field of activity of the Good Practice Guidelines is both academic and contact research in South Africa, it is important to keep in mind that they have no statutory power, unlike the MRC’s Guidelines, which were issued in accordance with a statute.\footnote{Nienaber \textit{Ethics and human rights in HIV-related clinical trials in Africa with specific reference to informed consent in preventative HIV vaccine efficacy trials in South Africa} at 104.} These guidelines (Good Practice Guidelines) contain nine chapters, and guideline nine is important to this study, as it this guideline emphasises ethical considerations for HIV/AIDS clinical and epidemiological research.\footnote{See Guideline 9.} In terms of the introduction of guideline nine, the HIV/AIDS research guidelines emanated out of a series of consultations held by the Task Group on Ethical Guidelines for HIV research. Although this document addresses challenges posed by HIV/AIDS, it does not deal specifically with HIV vaccine trials, which will be addressed by later guidelines. Guideline nine recognises that clinical and epidemiological research involves complex
ethical challenges. These include issues such as access to clinical trials and informed consent. According to this guideline, good research and ethical standards should be applied in both vulnerable and non-vulnerable communities.

5 CONCLUSION

This chapter explored the nature and importance of clinical research. The issue whether it crucial for the good of humanity and especially for the person who is at high risk of HIV infection to conduct such trials, was also addressed.

Another question addressed in this chapter was the classification of HIV vaccine efficacy trials as “therapeutic” or “non-therapeutic research”. It was concluded that any attempt to classify this type of trial into one of these categories seems trivial, as the focus must remain on the benefit to society as a whole of finding an effective vaccine for HIV. This chapter also looked at the relevant international and local guidelines dealing with research involving human beings.

In the next chapter, the inclusion of children in preventive HIV vaccine trials in terms of South African legislation will be discussed. This chapter will also turn to the issue of informed consent against the background of relevant human rights issues.
CHAPTER 3
LEGAL FRAMEWORK RELATING TO CHILDREN’S PARTICIPATION IN RESEARCH

Outline

1 Introduction

2 Legislation regulating the participation of children in research
   2.1 Introduction
   2.2 Constitution of the Republic of South Africa
   2.3 Children’s Act 38 of 2005
   2.4 Child Care Act 74 of 1983
   2.5 National Health Act 61 of 2003
   2.6 Choice on the Termination of Pregnancy Act 92 of 1996

3 Children’s participation in research
   3.1 Introduction
   3.2 Consent required for research
   3.3 Draft regulations
   3.4 Risks and benefits

4 Case law
   4.1 Introduction
   4.2 Castell v De Greef
   4.3 C v Minister of Correctional Services

5 Conclusion

1 INTRODUCTION

Given the number of people infected daily with HIV/AIDS throughout the world, and particularly in Sub-Saharan Africa, it is vital that something is done to stem the spread of this pandemic. HIV/AIDS is considered to be one of the greatest threats to the realisation of children’s rights in South Africa, because more than 40 per cent of the population of 45 million is under the age of eighteen, and they have an estimated HIV infection rate of
between 5 and 15 per cent.\textsuperscript{115} South African children are the most vulnerable group, and are at high risk of HIV infection.\textsuperscript{116} Considering these factors, it is essential that children should be vaccinated against HIV infection before they become sexually active. Their enrolment in clinical trials is a necessity in order to gather scientific data on the effect of vaccines on preventing infections or diseases relevant to them.

However, it is not that simple. Although it has been established that vaccine trials may ultimately benefit children all over the world, especially in Africa, their participation in this kind of research must be carried out in line with ethical standards. The decision to take part in research is influenced by several factors, for example, informed consent, as well as risk and benefit analysis, in order to prevent any kind of exploitation of children due to their vulnerable situation.

In this chapter the relevant South African statutes regulating the participation of children in research will be examined, and inconsistencies between these highlighted. This chapter will also focus on case law relating to informed consent.

2 LEGISLATION REGULATING THE PARTICIPATION OF CHILDREN IN RESEARCH

2.1 INTRODUCTION

This section will consider various legislative provisions relevant to the participation of children in research. An overview of these sections will provide a theoretical framework for the discussion of children’s participation in these trials in relation to issues such as informed consent, relevant fundamental human rights, as well as applicable case law.


2.2 CONSTITUTION OF THE REPUBLIC OF SOUTH AFRICA

Section 12(2)(c) of the Constitution states that “everyone has the right to bodily and psychological integrity, which includes the right not to be subjected to medical or scientific experiments without their informed consent”. This constitutional principle forms the over-arching framework for South African laws and guidelines on research with human volunteers. All laws, policies and ethical guidelines must be consistent with this provision. Van Wyk argues that the term “medical or scientific experimentation” as used in section 12(2)(c) of the Constitution, probably means nothing other than medical research. If one opts for a strict interpretation of section 12(2)(c), it would mean that all medical research (therapeutic or non-therapeutic) involving people who are not able to give their informed consent is prohibited. A less restrictive interpretation of this constitutional provision would result in a better balance between the rights of legally incompetent people and society’s interest in medical progress.

There are also other constitutional rights applicable to the medical research involving children, including the rights to human dignity and to privacy. The primary justification for privacy is respect for the individual, and the right to privacy and dignity are closely intertwined, as are the requirement of informed consent for medical treatment and the right to confidentiality.

Section 28(2) of the Constitution provides that “[a] child’s best interests are of paramount importance in every matter concerning the child”.

---

118 Strode 225.
119 Strode 225.
121 Van Wyk 590.
122 Van Wyk 590.
123 Section 10 states that everyone has “inherent dignity and the right to have their dignity respected and protected”, whereas section 14 states that “[e]veryone has the right to privacy, which includes the right not have – (a) their person or home searched; (b) their property searched; (c) their possessions seized; or (d) the privacy of their communications infringed.
124 Van der Poel J “Omissions and doctor’s legal duty to warn identifiable sexual partners of HIV positive patients” (1998) Responsa Meridiana at 34.
2.3 CHILDREN’S ACT\textsuperscript{125}

The Child Care Act\textsuperscript{126} 74 of 1983 has now finally been repealed, and has been replaced by the Children’s Act 38 of 2005. Section 129(2) of this Act now determine that a child may consent to his or her own medical treatment or that of his or her child, if the first-mentioned child is over the age of twelve years, is of sufficient maturity and has the mental capacity to understand the benefits, risks, social and other implications of the treatment. Subsection (3) of the same provision states that a child may consent to the performance of a surgical operation on himself or herself or his or her child if the first-mentioned child is over the age of twelve years, is sufficiently mature and has the mental capacity to understand the benefits, risks, social and other implications of the surgical procedure, and if the child is duly assisted by his or her parent or guardian. Further, if the child is below the age of twelve years, or above but of insufficient maturity or unable to understand the benefits, risks and social implications of the treatment, the parent, guardian or caregiver may consent to the child’s medical treatment.\textsuperscript{127}

It is important to note that although the Children’s Act has replaced the Child Care Act, at the time of preparation of this study, not all the provisions of the Children’s Act have come into operation. For the sake of completeness, the provisions regulation children’s consent to medical operations and medical treatment before the enactment of the Children’s Act should also be referred to.

2.4 CHILD CARE ACT

Section 39(4) of the now repealed Act provides that “a child above the age of fourteen years can independently consent to medical treatment, and that a person of eighteen years or older can independently consent to therapeutic medical research”. In the case of children under fourteen, it is generally accepted that parents or guardians may give proxy consent in respect of medical treatment.

\begin{flushleft}\textsuperscript{125} Act 38 of 2005 \textsuperscript{126} 74 of 1983, \textsuperscript{127} Section 129(4) of the Children’s Act.\end{flushleft}
2.5 NATIONAL HEALTH ACT\textsuperscript{128}

The National Health Act came into operation on 2 May 2005.\textsuperscript{129} This Act deals specifically with consent for minors’ participation in research. In terms of section 71(1)(b) of this Act, “research or experimentation on a living person may only be conducted with the written consent of the person after he or she has been informed of the objects of the research or experimentation and any possible positive or negative consequences on his or her health”. This provision is important with regard to the HIV vaccine trial, because the informed consent of the individual participant is required.

Informed consent implies that all information about the research and its known side-effects are provided to the participant. Section 71(2) requires consent from both the parent or guardian and the child, regardless of his or her age, for all research, including ‘therapeutic’ research. It states, in terms of the participation of children in research, that “[w]here research or experimentation is to be conducted on a minor for a therapeutic purpose, the research or experimentation may only be conducted – (a) if it is in the best interests of the minor; (b) in such a manner and on such conditions as may be prescribed; (c) with the consent of the parent or guardian of the child; and (d) if the minor is capable of understanding, with the consent of the minor”. This section will be critically examined below as its provisions contain inconsistencies with existing and proposed legislation and ethical guidelines.

Section 71(3)(a), which deals with non-therapeutic research, states that “where research or experimentation is to be conducted on a minor for a non-therapeutic purpose, the research or experimentation may only be conducted – (i) in such a manner and on such conditions as may be prescribed; (ii) with the consent of the Minister; (iii) with the consent of the parent or guardian of the minor; and (iv) if the minor is capable of

\textsuperscript{128} Act 61 of 2003

\textsuperscript{129} See Government Gazette No 27503 of 19 April 2005.
understanding, the consent of the minor”. This subsection constitutes the protection of children against unscrupulous practices.\textsuperscript{130} It will also be examined in more detail below.

The National Health Act reintroduces a distinction between therapeutic and non-therapeutic research,\textsuperscript{131} but does not define these terms. This classification is problematic as most research involves some interventions that are not intended to confer direct health-related benefits.\textsuperscript{132} It is understood that therapeutic research contains many non-therapeutic elements (that may have no benefit to an individual research participant), and, after all, in the case of the placebo trials, the therapeutic trial research participant may not benefit at all.\textsuperscript{133} Similarly, therapeutic research has at best merely the potential to benefit to the individual research participant.\textsuperscript{134} Therefore, considering these arguments, it would be difficult to make a distinction between “therapeutic” and “non-therapeutic” research. In the previous chapter, the question whether HIV preventive clinical trials should be classified as “therapeutic” or “non-therapeutic” was discussed, and it was concluded that it is indeed difficult to classify HIV preventive trials in either of the cited categories.\textsuperscript{135} Consequently, deciding whether the Minister’s permission is required for minors’ participation in preventive HIV-related research is also problematical.\textsuperscript{136}

2.6 CHOICE ON TERMINATION OF PREGNANCY ACT\textsuperscript{137}

In terms of this Act, any female of any age\textsuperscript{138} may have her pregnancy lawfully terminated upon request during the first twelve weeks of the gestation period of her

\begin{flushright}
\end{flushright}

\begin{flushright}
131 See paragraph 3.2.2 of chapter 2: “therapeutic” research is defined as research aimed to benefit the individual research participant, whereas “non-therapeutic” research is defined as research aimed to benefit other people than the research participant.
\end{flushright}

\begin{flushright}
\end{flushright}

\begin{flushright}
\end{flushright}

\begin{flushright}
134 Nienaber 674.
\end{flushright}

\begin{flushright}
135 See paragraph 3.3.2 of chapter 2
\end{flushright}

\begin{flushright}
136 Strode at 675.
\end{flushright}

\begin{flushright}
137 Act 92 of 1996.
\end{flushright}

\begin{flushright}
138 Section 1(xi) defines “woman” as any female person of any age.
\end{flushright}
pregnancy.\textsuperscript{139} Where the pregnant woman is a minor, the medical professional concerned is only under an obligation to advise her to consult her parents, guardian, family or friends before the pregnancy is terminated.\textsuperscript{140} Despite the fact that most of these first-trimester abortions do not involve any serious surgical interventions, it nevertheless creates an anomaly in the sense that a grave decision of this nature does not require any parental consult or guidance.\textsuperscript{141}

Therefore, this provision is in conflict with the terms of section 71(2) of the National Health Act, which requires the consent of parent or guardian for research or experimentation involving children.

3 CHILDREN'S PARTICIPATION IN RESEARCH

3.1 INTRODUCTION

Research with children presents a powerful tension between two sometimes conflicting social goals: protecting children from harm and exploitation, while at the same time increasing our body of knowledge about children in order to develop beneficial medical, psychological and social interventions.\textsuperscript{142} Three basic principles which are relevant to research involving human subjects are: informed consent, risk/benefit assessment and the selection of research subjects.\textsuperscript{143}

In the context of this study, emphasis will be placed on informed consent and risk/benefit assessment.

There are, however, inconsistencies between current laws concerning the consent needed for a minor’s participation in research. These inconsistencies are pointed out through a

\textsuperscript{139} Section 2(1)(a).
\textsuperscript{140} Slabbert MN “Parental access to minors’ health records in the South African health care context: Concerns and recommendations” 2004 (2) Potchefstroom Electronic Law Journal (PER) 1-21, 7.
\textsuperscript{141} Slabbert 7.
comparison of different provisions, ranging from the now repealed section 39(4) of the Child Care Act, sections 129(2) and 129(3) of the Children’s Act, as well as section 2(1)(a) of the Choice on Termination of Pregnancy Act, as well as sections 71(2) and 71(3) of the National Health Act. These contradictions can also be observed in the MRC Guidelines and Good Practice Guidelines. The next section will look more closely at these inconsistencies.

3.2 CONSENT REQUIRED FOR MEDICAL RESEARCH

Consent is grounds for justification, and excludes the unlawfulness of an action that would otherwise amount to a delict. Where such consent cannot be obtained due to the incapacity of the participant (in the case of children), proxy consent of the parent or guardian is recommended. Van Oosten outlines the requisites for consent as follows:

- Consent must be legally recognised, in other words, it must accord with the *boni mores* or public policy.
- The person who consents must have the legal capacity to consent, that is, the consenting person must be legally and factually capable of understanding information and deciding on a course of action.
- In order to be valid, consent needs to be appropriately informed.
- Consent must be free and voluntary/clear and unequivocal/comprehensive/revocable.

---

144 Contradiction with section 71(2) of the National Health Act, see paragraph 3.2.5.
146 Van Wyk 41.
147 Van Oosten F “The law and ethics of information and consent in medical research ” 2000 (63) THRHR 5-31, at 14-30.
148 Van Oosten 14.
149 Nienaber *Ethics and human rights in HIV-related clinical trials in Africa with specific reference to informed consent in preventative HIV vaccine efficacy trials in South Africa* 422.
151 Van Oosten 29.
Informed consent is regarded as one of the primary ways of ensuring that research participants are protected against exploitation.\textsuperscript{152} The concept of informed consent was affirmed in the case of \textit{Castell v De Greef},\textsuperscript{153} which will be discussed below. In this case, the court stated that a patient should be informed of all material risks inherent in the proposed treatment.

For the purpose of this study, researchers may be said to have extra responsibilities when the participants are children.\textsuperscript{154} It is necessary to ensure that a child fully understands the implications of the research. The question arising, however, is whether children have the capacity to give consent to participate in HIV vaccine trial research. The position regarding the informed consent of children who are participating in research appears is far from clear as a result of conflicting provisions.

In the past, section 39(4) of the Child Care Act provided that children of fourteen years and older could independently consent to medical treatment (which included medical research),\textsuperscript{155} and children of eighteen and older could independently consent to medical interventions. For children under the age of fourteen, the proxy consent of a parent or guardian was required in respect of medical research. Presently, in terms of the Children’s Act, sections 129(2) and 129(3) have lowered the age to consent to medical treatment to twelve years by stating that children of twelve years and above should be entitled to independently consent to all medical interventions, provided that they have sufficient understanding. Proxy consent of a parent, guardian or caregiver is required in terms of section 129(4) of the Children’s Act. The parent’s, guardian’s or caregiver’s consent is also required if the child is under the age of twelve years, or if the child, despite being twelve years old or above, does not have the sufficient maturity or ability to understand the benefits, risks and social implications of the interventions.

\textsuperscript{152} Nienaber 360.
\textsuperscript{153} 1994 (4) SA 408 (C).
\textsuperscript{155} Van Wyk “HIV preventative vaccine research on children: Is it possible in terms of South African law and research guidelines?” at 37.
The National Health Act, on the other hand, does not provide for a child a capacity to give independent consent to participate in research, as was the case with the Child Care Act\textsuperscript{156} and is presently permitted in terms of the Children’s Act.\textsuperscript{157} Thus, children will be assisted by their parent or legal guardian if they wish to be involved in research. This may be seen as an impediment to their privacy, and minors will refuse to take part in research because seeking parental consent will necessitate a violation to their privacy.\textsuperscript{158}

Furthermore, section 71(2) of the National Health Act stipulates that the consent can only be given by the minor if he or she is capable of understanding, which differs from the approach taken by the Children’s Act, which determines that the minor’s wishes are important, and should be taken into consideration, even if he or she cannot understand.\textsuperscript{159}

The National Health Act, when referring to parental consent for medical interventions, in addition refers to “a” parent or guardian.\textsuperscript{160} The consent of one parent or guardian may therefore be sufficient. The fact that only a “parent” or “guardian” may consent to the minor’s participation in research, and not another person that has the care of the minor may pose problem in the case of children in children’s homes or other places of safety, or where their parents cannot be reached.\textsuperscript{161} One consequence of this requirement is that it may result in the exclusion of children without parents or guardians from research which may be of direct benefit to them.\textsuperscript{162}

\textsuperscript{156} See section 39(4) which allowed a child of fourteen years and older to independently consent to “medical research”.

\textsuperscript{157} In terms of sections 129(2) and 129(3) which allow the child to independently consent to medical treatment and surgical operation if the child is twelve years and older, provided that the child has sufficient understanding of the procedures or treatment.

\textsuperscript{158} See Nienaber “The statutory regulation of children’s participation in HIV-related clinical research: More questions than answers” at 674.

\textsuperscript{159} Nienaber 674.

\textsuperscript{160} In terms of section 71(2) of the National Health Act, therapeutic research may be conducted on minor only with the consent of the minor’s parents or legal guardians, as well as the minor himself if capable of understanding.

\textsuperscript{161} Nienaber “The statutory regulation of children’s participation in HIV-related clinical research: More questions than answers” at 673.

\textsuperscript{162} Nienaber 673. The child is not strictly a “user” as is defined in the National Health Act as a person “receiving treatment” in a health establishment, or “using” a health establishment (see definition of “user” in section 1 of the Act.
The National Health Act\textsuperscript{163} requires also that in the case of research of a therapeutic nature to be conducted, that the “best interests” of the minor be taken into account. However, there is no guidance provided in the Act for establishing what the “best interests” of the minor are. This demands an assessment of whether or not subjecting a minor to a particular intervention is in their best interests, by weighing up various factors, such as the probability and magnitude of risks and benefits.\textsuperscript{164}

In the case of non-therapeutic research on minors, the consent of the Minister is required.\textsuperscript{165} By making ministerial approval compulsory, however, where in the past it was left to individual ethics committees to decide whether a proposed research project is ethically justified or not, section 71(3) not only lengthens the approval process of such protocols, but also removes the discretionary powers of research ethics committees.\textsuperscript{166}

The consent of the Minister is required in addition to the consent of the parent or guardian of the minor. This requirement has a number of ambiguities, including which research falls into its scope and its place in the sequence of approvals.\textsuperscript{167} Moreover, the Minister may not give consent to the minor’s participation in non-therapeutic research if – (i) the object of the research or experimentation can also be achieved if it is conducted on an adult;\textsuperscript{168} (ii) the research poses a “significant risk” to the health of the minor;\textsuperscript{169} or (iii) there is “some risk” to the health or wellbeing of the minor and the “potential benefit” of the research or experimentation does not significantly outweigh that risk.\textsuperscript{170} Difficulties may arise as the Act does not define “significant risk”, nor is it a term used in South African ethical guidelines.\textsuperscript{171} Although the National Health Act attempts to create legal certainty regarding child participation in research, it fails to provide objective, clearly defined risk standards for determining when it is lawful for a parent or guardian to

\begin{itemize}
\item \textsuperscript{163} Section 71(2).
\item \textsuperscript{164} See Strode at 226.
\item \textsuperscript{165} Section 71(3) of the National Health Act.
\item \textsuperscript{166} Nienaber “The statutory regulation of children’s participation in HIV-related clinical research: More questions than answers” at 674.
\item \textsuperscript{168} Section 71(3)(b)(i).
\item \textsuperscript{169} Section 71(3)(b)(iv).
\item \textsuperscript{170} Section 71(3)(b)(v).
\item \textsuperscript{171} See Strode at 226.
\end{itemize}
consent to research with an adolescent.\textsuperscript{172} It is important to note that the description of “minor” in the National Health Act be read in conjunction with the Constitution and the Children’s Act, which set the age at 18 years.\textsuperscript{173}

Two ethical guidelines relevant to HIV vaccine research\textsuperscript{174} also offer contradictory provisions regarding children’s consent to research. Section 9.6 of the Good Practice Guidelines, which deals with informed consent, neither mentions the age of independent consent to research, nor the person who may give consent. This approach differs from Guideline 12.7 of the MRC Guidelines,\textsuperscript{175} which provides that legal requirements for capacity to consent must be met in order for children to participate in research. Furthermore, persons above the age of eighteen who are sound of mind may give consent to vaccine trial participation - if the person is below the age of eighteen, proxy consent from a parent or legal guardian is required. In certain circumstances, a person below eighteen years can consent independently. Guideline 18.7.1.1, along the same lines, provides that in South Africa, the involvement of a child (below the age of eighteen) in HIV vaccine research requires the proxy consent of a parent or legal guardian, as well as consent of the child, according to his or her level of maturity.

In order to highlight the inconsistencies between the different Acts and ethical guidelines discussed above, a table based on Nienaber’s example,\textsuperscript{176} is presented below:

\begin{table}[h]
\centering
\begin{tabular}{|c|c|}
\hline
\textbf{Age} & \textbf{Consent}\tabularnewline
\hline
\textnormal{Below 18 years} & Proxy consent of a parent or legal guardian\tabularnewline
\textnormal{Above 18 years} & Independent consent\tabularnewline
\hline
\end{tabular}
\caption{Consent to HIV vaccine research in South Africa}
\end{table}

\textsuperscript{172} Strode 226.
\textsuperscript{173} Section 17 of the Children’s Act.
\textsuperscript{175} See Book 5.
\textsuperscript{176} See Nienaber Ethics and human rights in HIV-related clinical trials in Africa with specific reference to informed consent in preventative HIV vaccine efficacy trials in South Africa at 469 and also, in general, Nienaber “The statutory regulation of children’s participation in HIV-related clinical research: More questions than answers”.

46
<table>
<thead>
<tr>
<th>Sources of Law</th>
<th>Age of independent Consent</th>
<th>Who may give Consent</th>
</tr>
</thead>
</table>
| Child Care act 74 of 1983 (now repealed; replaced by the Children’s Act 38 of 2005 below) | “To medical treatment” - 14 years and above  
“To medical operation” - 18 years and above | Parent or guardian of the child if under 14 years of age, and for an operation if the child is under 18 years of age. |
| Children’s Act 38 of 2005 | To “medical treatment” - 12 years and above and of sufficient maturity and mental capacity.  
To “surgical operation” - 12 years and above, or if child is of insufficient maturity, with the assistance of a parent or guardian. | Parent, guardian or care-giver |
| National Health Act 61 of 2003 | 18 years of age  
For non-therapeutic research on minor (under the age of 18) | Parent or guardian  
Consent of the Minister |
| Choice on Termination of Pregnancy Act 92 of 1996 | Any age | N/A |
| MRC Guidelines | 18 years and above and of sound mind. In certain circumstances, children below the age of 18 years can give his/her own consent. Consent of the child. | Proxy consent of a parent or legal guardian |
| Good Practice Guidelines | None mentioned | None mentioned |
### 3.3 DRAFT HEALTH RESEARCH REGULATIONS

Relevant to this study are the “Regulations relating to research on human subjects” (draft health research regulations),\(^{177}\) issued in terms of section 90 of the National Health Act.

Although its purpose is to supplement the requirements for the participation of minors in research in terms of 71(2)(3) of the National Health Act, clause 4 of the draft health research regulations neither elucidates, nor elaborates on the position set out in section 71 of the National Health Act.\(^ {178}\) It states that “[c]hildren can only participate in research in instances where the parent or legal guardian of the child gives consent for such a child to participate”. And, the “refusal to participate by a child should precede the consent of the parent/legal guardian”.\(^ {179}\) As seen above, section 71(2) of the National Health requires the consent of parent and legal guardian for therapeutic research and for non-therapeutic research, and section 71(3)(ii) requires the consent of the Minister. The question arising is whether the consent of the Minister in the case of non-therapeutic research is no longer necessary in terms of clause 4. Clause 4 also does not clarify the uncertainty in respect of who is permitted to consent in the case of children who are without parents or guardians and who are looked after by “care-givers”.\(^ {180}\) The addition of the word “legal” in the clause does not offer a solution because a “care-giver” is not a “legal” guardian in terms of South African law.\(^ {181}\)

The second part of the clause 4(c) is also problematical. The statement, “refusal to participate by a child should precede the consent of the parent/legal guardian” seems to suggest that the autonomous decision of a child is no longer relevant, as a child who refuses to participate in research may be forced by his or her parents or legal guardians to

---

\(^{177}\) GG 29637, published 23 February 2007.

\(^{178}\) See Nienaber Ethics and human rights in HIV-related clinical trials in Africa with specific reference to informed consent in preventative HIV vaccine efficacy trials in South Africa 470.

\(^{179}\) Clause 4(c) of the draft health research regulations.

\(^{180}\) Nienaber Ethics and human rights in HIV-related clinical trials in Africa with specific reference to informed consent in preventative HIV vaccine efficacy trials in South Africa 471.

\(^{181}\) Nienaber 471.
do so. This possibility is not only out of the step with current legislation,\textsuperscript{182} but is also likely to be considered \textit{contra bonus mores}.\textsuperscript{183}

3.4 \textbf{RISKS AND BENEFITS}

Risk assessment is an activity in which everyone is daily involved - risks are a fact of life.\textsuperscript{184} Participation in HIV preventive vaccine research may involve physiological,\textsuperscript{185} psychological\textsuperscript{186} and social\textsuperscript{187} risks.\textsuperscript{188}

The term “risk” is material to consent in the sense that there is a risk attached to research undertaken with consent, depending on whether such research is therapeutic or non-therapeutic, or invasive (intrusive)\textsuperscript{189} or non-invasive (non-intrusive).\textsuperscript{190} In terms of so-called “risk/benefit analysis”, the risk to which the patient is exposed must be justifiable in relation to the value of the information sought, and “risk” refers to both the probability of harm resulting from an activity and to its magnitude.\textsuperscript{191} Beneficence, in short, requires that the possible benefits should be maximised and possible harms be minimised, not only for individual research participants, but also for society in general.\textsuperscript{192}

Inconsistency also exists between guidelines 7.1.3.2 of the revised MRC Guidelines\textsuperscript{193} and section 71(3)(b) of the National Health Act concerning the risk standard in case of

\begin{footnotesize}
\begin{enumerate}
\item See sections 29(2) and 29(3) of the Children’s Act 38 of 2005.
\item Nienaber 470.
\item The purpose of an HIV preventive vaccine is to induce an immunological response to counteract the HI virus if it enters the human body, or to prevent it from entering at all.
\item Eg stress related to participation, lengthy trials involving intensely intimate matters and repeated HIV testing ; stigma and discrimination that may result if a volunteer’s participation becomes publicly known, anxiety related to exposure to culturally different scientific medical concepts, etc.
\item Eg discrimination and stigma from the community.
\item Guideline 9.2 of the MRC Guidelines, book V.
\item Eg research which involves making observations without any direct interference with the subject (such as research involving the use of personal records).
\item Eg research which involves interference with the subject (psychological intrusion, including intrusion on privacy or physical invasion). See Van Oosten 11.
\item Van Oosten 11.
\item Van Wyk “Guidelines on medical research ethics, medical ‘experimentation’ and the Constitution” at 7.
\item See Guideline 7.1.3.2 of Book 1 entitled “General principles”. Non-therapeutic research on healthy
\end{enumerate}
\end{footnotesize}
non-therapeutic research. Indeed, the National Health Act's risk standard for “non-therapeutic” research is that of not “significant” whereas the reference to the risk standard in Guideline 12 of the Medical Research Council for “non-therapeutic” research refers to risk that is “negligible” — a risk so small it may be ignored.

4 RELEVANT CASE LAW

4.1 INTRODUCTION

Consent is grounds for justification which excludes the wrongfulness of an action. In the absence of informed consent, medical interventions are, as a result, unlawful or wrong. The broad concept of informed consent was affirmed in the cases of Castell v De Greef and in C v Minister of Correctional Services.

4.2 Castell v De Greef

In this case the defendant, a plastic surgeon, was sued for damages by the plaintiff for alleged negligence in performing a surgical operation known as a subcutaneous mastectomy. The court concluded that the medical practitioner has failed to warn his patient of the “material risks” and complications which might flow from a surgical operation or other medical treatment.

This case is relevant to the present study because, applied to the context of research with children; this means that a minor (if displaying sufficient maturity and ability to understand the risks and benefits of the procedure), as well his parents or legal guardian, should be informed about the risks and benefits posed by the HIV preventive clinical

---

children (under the age of 18 years, according to the Constitution) should be approved only if the research places the child at no more than negligible risk) (see also Guideline 9.12.4.3).

See Strode 267.

1994 (4) SA 409( C).

1996 (4) SA 292 (T).

A risk is material if in the particular circumstance: (a) the medical practitioner is or should reasonably be aware that the particular patient, if warned of the risk, would be likely to attach significance to it; or (b) a reasonable person in the patient’s position, if warned of the risk, would be likely to attach significance to it.
research before giving their consent. The risks for participating in research lie for example in the serious social and psychological implications of a positive test result to which a reasonable person is likely to attach significance (in case of non-therapeutic preventive HIV-related research, the participants are HIV negative).  

The legal consequences of a medical intervention performed without the patient’s lawful consent are that the doctor or hospital may incur liability for breach of contract, civil or criminal assault (a violation of physical integrity), civil or criminal *iniuria* (a violation of dignity/privacy), or negligence, as the case may be, or that the doctor or hospital may be unable to recover a professional fee.

In *C v Minister of Correctional Services*, the concept of informed consent and pre-and post-test counselling in the context of HIV testing was examined in more detail.

### 4.3 *C v Minister of Correctional Services*

In this case, the main issue was the conducting of an HIV test on a prisoner without his informed consent, at the time when the Department of Correctional Services had adopted the principle that informed consent was a prerequisite for testing prisoners and had specified what norms were applicable. The Court awarded damages because of the failure of prison authorities to provide the prisoner with pre- and post-test counselling. It was stated that failure to provide the necessary counselling resulted directly in the deterioration of the prisoner’s health.

---

198 See Nienaber “The statutory regulation of children’s participation in HIV-related clinical research: More questions than answers” at 675.

199 Van Oosten F “Castell v De Greef and the doctrine of informed consent: Medical paternalism ousted in favour of patient autonomy” (1996) *De Jure* 164-179, at 166. On breach of contract, see *Behrmann v Klugman* 1998 (W) (unreported); on liability for assault, see *Stoffberg v Elliot* 1923 CPD 148 ff; *Layton & Layton v Wilcox & Higginson* 1944 SR 48 50; *Lampert v Hefer* 1955 2 SA 507 (A) 508E-F; *Esterhuizen v Administrator Transvaal* 1957 (3) SA 710 (T) at 718 ff; *S v Sikunyana* 1961 3 SA 226 (C) 232F-G; *Burger v Administrateur Kaap* 1990 (1) SA 483 at 489; *S v Kiti* 1994 SACR 14 (E) 18f-g; *S v Binta* 1993 2 SACR 553 (C) 561 j-562c; on liability for negligence, see *Lymberry v Jefferies* 1925 AD 236: *Prowse v Kaplan* 1933 EDL 257; *Allot v Paterson & Jackson* 1936 SR 221, 222-224; *Layton & Layton v Wilcox & Higginson* 50, *Dube v Administrator Transvaal* 1963 4 SA 260 (W) 269C-270 A; *Soumbasis v Administrator of the Orange Free State* 1989 (O) (unreported); on liability for civil *iniuria*, see *Stoffberg v Elliott* 152; and on the recovery of a professional fee, see *McCallum v Hallen* 1916 EDL 74.
This case is relevant because applied to the context of this study; it has demonstrated that the failure to obtain informed consent from a research participant may have a range of serious consequences. All research participants must be advised about the purpose of the research, the known side-effect of drugs and eventually any possible negative or positive health consequences. Time of reflection must be given to them for any approval or not to participate in the research.

5 CONCLUSION

This chapter has highlighted the requirements for children to take part in research, and places emphasis on the requirement of informed consent and the risks/benefits analysis. Given the fact that children are in a vulnerable situation and should be protected against any kind of exploitation, obtaining informed consent is very important in order to ensure their protection. This chapter also emphasises the inconsistencies that exist in South African legislation and ethical guidelines regarding the issue of informed consent in the context of HIV vaccine trials involving children. These inconsistencies make the issue of the participation of children in research unclear. In view of the urgent need of enrolling children in this kind of research, one hopes that these inconsistencies be addressed in order to harmonise all the conflicting provisions.

200 See Strode at 265.
CHAPTER 4
CONCLUSION AND RECOMMENDATIONS

Outline

1. Introduction
2. Summary
3. Conclusion
4. Recommendations

1 INTRODUCTION

The research question, as posed in the beginning of this study, was as following: Is the enrollment of healthy children in HIV vaccine trials allowed in terms of the South African Constitution, current legislation and relevant guidelines?

2 SUMMARY

This study has demonstrated that HIV/AIDS presents a real threat to humanity and particularly to the welfare of children. It is therefore essential to undertake research with children in order to gather scientific data on the effect of vaccines on preventing infection or disease relevant to them. There is also a need to protect children from harm resulting from research, and this also needs to be carefully considered.

The Joint United Nations Programme on HIV/AIDS notes that children should be recipients of future HIV preventive vaccines, and should be included in clinical trials in order to verify the safety, immunogenicity and efficacy of vaccines from their point of view.\(^{201}\) Efforts should be made to design vaccine development programmes that address

the particular ethical and legal considerations relevant to children, and to safeguard their
rights and welfare during participation in research.202

Two key questions that had to be answered in the context of this study are firstly the
question whether HIV clinical trials are “therapeutic” or “non-therapeutic” trials, and
secondly, in view of the conflicting statutory provisions relevant to children’s
participation in research, who should consent to children’s participation in this type of
research.

With regard to the first issue, although it has led to differing opinion amongst South
African scholars, this study supports the view of scholars who argue that it would be
difficult to fit HIV-preventive clinical trials into either the category of “therapeutic” or
“non-therapeutic” research.203 This view must be supported, because of the impossibility
of distinguishing between “therapeutic” and “non-therapeutic” research.

In terms of the second issue, in the South African context, the ethical-legal framework
governing research involving children contains provisions which are contradictory,
especially relating to the person who should give informed consent. These inconsistencies
make the position regarding the informed consent of children who are participating in
research unclear, and consequently their enrolment in HIV clinical trials.

3 CONCLUSION

It is clear that the question of the participation of children in HIV clinical research in
South Africa poses many challenges, as South African law and ethical guidelines are
inconsistent. Children’s participation, especially on the African continent, in HIV
preventive vaccine trials, is vital.

202 Ibid.
203 Nienaber A “The statutory regulation of children’s participation in HIV-related clinical research:
more question than answers” 2008 (71) THRHR 671-674, at 675.
The National Health Act,\textsuperscript{204} as was seen above, reintroduced a distinction between “therapeutic” and “non-therapeutic” research, but fails to define these terms. The provisions of this Act at these relate to children’s participation in clinical trials, are in conflict with relevant ethical guidelines. There is also not an objective and clear risk standard for what constitutes “therapeutic” and “non-therapeutic” research.\textsuperscript{205} Furthermore, the requirement in terms of the National Health Act regarding the approval of the Minister in cases of “non-therapeutic” research involving children, has a number of ambiguities, including the problem determining what type of research falls into this scope, as well as its place in the sequence of approvals.\textsuperscript{206}

To sum up, the Draft Health Research Regulations,\textsuperscript{207} instead of bringing more clarity on the contradictory and inconsistent provisions of the National Health Act, have created more confusion.\textsuperscript{208} Therefore, although the enrolment of children in HIV-preventive clinical trials appears to be lawful in terms of the South African Constitution, current legislation and relevant guidelines, it needs to be accompanied by much clearer legislation and ethical guidelines to remove any of the inconsistencies pointed out in this study.

4 RECOMMENDATIONS

In the context of this study, the following recommendations are suggested:

- Revision of the ambiguous sections of the National Health Act in order to clear up the inconsistencies and contradictions created by its provisions, especially those relating to the question of the participation of children in research;

\textsuperscript{204} Act 61 of 2003, see section 71(2).
\textsuperscript{205} Strode A et al “Ethical and legal challenges in enrolling adolescents in medical research in South Africa: implication for HIV vaccine trials” 2005 (101) South Africa Journal of Science, 224-228.
\textsuperscript{207} GG 29637, published 23 February 2007.
\textsuperscript{208} Nienaber 677.
• A revision of the Draft Health Research Regulations in order to harmonise the position relating to children’s participation in research with the corresponding provisions of the National Health Act;

• A revision of the relevant ethical guidelines in order to ensure that these correspond to the legal position created by the above statutory provisions.

• Finally, considerable training is in addition required to ensure that the interests and welfare of children participants are guaranteed, as their participation is critical to HIV research and prevention and general health promotion.
BIBLIOGRAPHY

CASES

Allot v Paterson & Jackson 1936 SR 221
Behrmann v Klugman 1998 (W) (unreported)
Burger v Administrateur Kaap 1990 (1) SA 483 (C)
C v Minister of Correctional Services 1996 (4) SA 292 (T)
Castell v De Greef 1994 (4) SA 409 (C)
Dube v Administrator Transvaal 1963 4 SA 260 (W)
Esterhuizen v Administrator Transvaal 1957 (3) SA 710 (T)
Lampert v Hefer 1955 2 SA 507 (A)
Layton & Layton v Wilcox & Higginson 1944 SR 48
Lymbery v Jefferies 1925 AD 236
McCallum v Hallen 1916 EDL 74
Prowse v Kaplan 1933 EDL 257
S v Binta 1993 2 SACR 553 (C)
S v Kiti 1994 SACR 14 (E)
S v Sikunyana 1961 3 SA 226 (C)
Soumbasis v Administrator of the Orange Free State 1989 (O) (unreported);
Stoffberg v Elliot 1923 CPD 148

NATIONAL CONSTITUTION


ETHICAL GUIDELINES

South Africa
Department of Health: *Guidelines for good practice in the conduct of clinical trials on human participants in South Africa* (2000)


**International**


The Belmont Report

The Nuremberg Code


World Medical Association Declaration of Helsinki: *Recommendations guiding medical doctors in biomedical research involving human subjects* (adopted by the 18th World Medical Assembly, Helsinki, Finland, 1964, and as revised by the 29th World Medical Assembly, Tokyo, Japan, 1975)

**LEGISLATION**

**South Africa**

Child Care Act 74 of 1983

Children’s Act 38 of 2005
Choice on Termination of Pregnancy Act 92 of 1996

Medical Research Council Act 58 of 1991

National Health Act 61 of 2003

REGULATIONS

Draft regulations relating to research on human subjects (South Africa Government Gazette 29637)

MISCELLANEOUS DOCUMENTS


THESIS


BOOKS

Annas G *Informed consent to human experimentation: The subject’s dilemma* (1977, Mass: Ballinger)


Kerns T A *Ethical issues in HIV vaccines trial* (19979, Seattle: North Seattle Community College)


Rick N G *Drugs from discovery to approval* (2004, Hoboken: John Wiley & Sons)


JOURNALS ARTICLES AND CHAPTERS IN BOOKS

B


D


F

Francis D P et al “Candidate HIV/AIDS vaccines: Lessons learned from the world’s first phase III efficacy trials” (editorial review) (2003) 17 The Lancet 147

H


K

Karim S S “Conducting HIV vaccine trials in South Africa” (2002) 20 CME 588


L

61
Ladimer I “Biological research for the community: Legal and ethical perspectives” (1977) 55 *Bulletin of the World Health Organisation* 111-115


Nienaber A “The statutory regulation of children’s participation in HIV-related clinical research: more question than answers” (2008) 71 *THRHR* 671-674


Schoub B “Vaccination as an intervention against viral diseases: Will this work for HIV?” (1992) 20 *CME* 561


Slack C *et al* “Enrolling adolescents in HIV vaccine trials: Reflections on legal complexities from South Africa” (2007) 8 *BMC Medical Ethics* 5


Van der Poel J “Omissions and doctor’s legal duty to warn identifiable sexual partners of HIV positive patients” (1998) *Responsa Meridiana* 18-40


Van Oosten “The law and ethics of information and consent in medical research” (2000) *THRHR* 63 5-31

Van Wyk “Guidelines on medical research ethics, medical ‘experimentation’ and the Constitution” (2001) 64 *THRHR* 3-22


**INTERNET SOURCES**

Belmont Report accessed at:


